Biocare and Proteintech Forge Alliance to Power Digital Pathology

SAN FRANCISCO and ROSEMONT, Ill. – March 23, 2026 – In a strategic move poised to reshape the landscape of medical diagnostics, Biocare Medical and Proteintech have announced a significant collaboration to develop next-generation antibody technologies. The partnership unites Proteintech's deep expertise in antibody engineering with Biocare's leadership in diagnostic assay development, aiming to solve long-standing challenges in pathology and fuel the ongoing transition to digital workflows.

The co-development agreement focuses on creating high-performance, "digital-ready" antibody reagents, the foundational tools for identifying diseases in tissue samples. This initiative directly addresses the mounting pressures on pathology laboratories worldwide, which are struggling to keep pace with rising diagnostic demands and persistent workforce shortages.

"Pathology laboratories are under increasing pressure to deliver accurate results while managing growing case volumes and persistent workforce shortages," said Luis de Luzuriaga, CEO at Biocare Medical. "By combining Proteintech's advanced antibody engineering capabilities with Biocare's diagnostic validation expertise, this collaboration strengthens our ability to deliver digital-ready reagents that support reliable, reproducible assays across modern pathology workflows."

Addressing a Crisis in the Lab

The field of pathology is at a critical juncture. The global market for immunohistochemistry (IHC), a core technique for cancer diagnosis, is projected to grow from $3.42 billion in 2024 to over $5.4 billion by 2032. This surge is driven by an increasing cancer caseload and the growing complexity of diagnostics. However, the number of practicing pathologists has not kept pace, creating a significant strain on laboratories.

Digital pathology—the practice of managing and interpreting diagnostic information from digitized glass slides—offers a powerful solution. It streamlines workflows, enables remote consultations to alleviate staffing bottlenecks, and paves the way for AI-powered image analysis that can enhance diagnostic accuracy. The digital pathology market is expanding rapidly, with a projected compound annual growth rate of nearly 12%. Yet, its full potential is hobbled by a fundamental challenge: the inconsistency of the reagents used to stain tissue samples.

For decades, the life science industry has grappled with antibody reproducibility. Inconsistent performance between different batches of antibodies can lead to variable staining, compromising the reliability of diagnostic data and hindering the standardization of assays. This collaboration aims to tackle that problem at its source by engineering a new class of highly consistent antibodies designed specifically for the rigors of the modern, digitized lab.

Engineering a New Standard for Antibody Precision

The partnership's technological core lies in the fusion of two complementary strengths. Proteintech brings its proprietary ABCE™ (Antigen-Specific B-Cell Cloning & Engineering) platform to the table. This sophisticated system enables the rapid, high-throughput development of recombinant antibodies. Unlike traditional methods, the ABCE™ platform isolates antibody-producing cells and clones their genetic sequences, preserving the native pairing of antibody chains that is critical for specificity and function. The result is a genetically defined product that offers exceptional batch-to-batch consistency—a crucial attribute for reproducible diagnostics.

"Proteintech has spent decades building deep expertise in antibody development and protein engineering," stated Jason Li, President and CEO at Proteintech. "Working with Biocare provides an exciting opportunity to extend these capabilities into diagnostic pathology workflows and help bring advanced antibody engineering technologies to applications that support tissue-based diagnostics, translational research, and precision oncology."

Biocare Medical will leverage its extensive experience in diagnostic immunohistochemistry to validate these engineered antibodies and integrate them into robust, IVD-grade assays. With a portfolio of over 300 IVD antibodies designed for multi-platform compatibility, Biocare has a proven track record of creating solutions that allow laboratories to standardize staining performance across diverse instrument environments. This expertise is vital to ensure the new reagents perform reliably in real-world clinical settings, from automated staining instruments to digital slide scanners and image analysis software.

Fueling the Next Wave of Precision Oncology

The implications of this collaboration extend far beyond improving laboratory efficiency. The development of reliable, standardized tissue-based biomarkers is the bedrock of precision oncology. The ability to accurately identify specific molecular targets within a patient's tumor is essential for guiding targeted therapies, including the rapidly growing class of Antibody-Drug Conjugates (ADCs).

ADCs are highly targeted therapies that deliver potent cytotoxic agents directly to cancer cells. Their success hinges on the precise identification of a target antigen, which requires exceptionally specific and reliable diagnostic antibodies. Likewise, companion diagnostics (CDx)—tests used to determine a patient's eligibility for a specific drug—demand the utmost rigor in validation and reproducibility. By providing a new generation of IVD-grade antibodies, the Biocare-Proteintech alliance is set to provide the high-quality tools needed to advance these cutting-edge treatments.

Furthermore, the initiative will support emerging technologies like spatial biology, which analyzes the spatial organization of molecules within a tissue sample to provide deeper insights into the tumor microenvironment. As these powerful research tools move toward clinical applications, their adoption will depend on the very IVD-grade quality, assay standardization, and rigorous quality control that this partnership is built to deliver.

A Strategic Blueprint in a Competitive Landscape

This collaboration represents a savvy strategic maneuver in a competitive diagnostics market dominated by giants like Roche Ventana, Leica Biosystems, and Agilent Dako. While these larger players offer comprehensive workflow solutions, Biocare and Proteintech are creating a focused partnership that leverages their specialized strengths to address a critical, industry-wide vulnerability: reagent quality.

By combining Proteintech's upstream antibody engineering prowess, which is backed by GMP-grade manufacturing and ISO 13485 compliance, with Biocare's downstream validation and market access, the two companies are creating a powerful synergy. This approach aligns perfectly with the evolving regulatory environment. Regulatory bodies like the U.S. Food and Drug Administration (FDA) have increasingly emphasized the need for better standardization and have identified gaps in how digital diagnostic systems are validated. The collaboration's intense focus on reproducibility directly addresses these regulatory concerns, potentially creating a smoother path to market for future diagnostic products.

Ultimately, this partnership serves as a blueprint for innovation in the biotech and diagnostics sectors. By joining forces to solve a fundamental technical challenge, Biocare Medical and Proteintech are not only positioning themselves for market leadership but are also building the foundational infrastructure needed to support a new era of more accurate, reliable, and personalized medicine.